secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vaxart, Inc. (VXRT)
CIK:        0000072444
Form:       8-K
Filed at:   2024-09-30T23:59:59+00:00
Accession:  0001437749-24-030276
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vaxart initiates sentinel cohort of Phase 2b oral COVID-19 vaccine trial; BARDA raises funding to $456M
--------------------------------------------------------------------------------

- Modification No. 3 increased total estimated ceiling to ~$456.1M (+$3.2M) and allotted funding to ~$96.5M (+$30.8M).
- Sentinel cohort of 400 participants (200 Vaxart oral pill, 200 mRNA comparator) begins; 30-day safety data will trigger enrollment of 10,000.
- Trial will measure efficacy against symptomatic/asymptomatic disease, systemic and mucosal immunity, and safety.
- Funding via Project NextGen (BARDA); full Phase 2b primary efficacy analysis at 12 months post-vaccination.
- Vaxart's XBB vaccine construct and newly funded KP.2-targeting construct are part of the study.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/72444/000143774924030276/0001437749-24-030276-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/72444/000143774924030276/vxrt20240930_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-030276

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer